TVTY · Tivity Health, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 | Q1 '20 | Q4 '19 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $127.51M | - | $126.29M | $120.07M | $108.08M | - | $254.91M | $262.60M | $337.65M | - |
| Cost of Revenue | $78.42M | - | $74.51M | $68.64M | $57.28M | - | $122.81M | $118.24M | $199.16M | - |
| Gross Profit | $49.10M | - | $51.78M | $51.43M | $50.80M | - | $132.10M | $144.36M | $138.50M | - |
| R&D | - | - | - | - | - | - | - | - | - | - |
| SG&A | $10.70M | - | $10.64M | $9.65M | $9.70M | - | $26.72M | $23.47M | $28.01M | - |
| Total Operating Expenses | - | - | - | - | - | - | - | - | - | - |
| D&A | $3.21M | - | $2.66M | $2.74M | $2.68M | - | $13.31M | $12.92M | $14.76M | - |
| Operating Income | $32.41M | - | $37.03M | $37.64M | $37.19M | - | ($19.78M) | $55.85M | ($191.59M) | - |
| Interest Expense | $6.99M | - | $7.35M | $9.40M | $10.76M | - | $20.39M | $21.23M | $21.66M | - |
| Income Tax | $8.09M | - | $8.93M | $187.0K | $7.62M | - | $2.24M | $6.11M | ($15.15M) | - |
| Net Income | $581.0K | - | $102.77M | $8.36M | $19.14M | - | ($42.42M) | $28.51M | ($198.11M) | - |
| EPS - Basic | $0.01 | - | $2.07 | $0.17 | $0.39 | - | ($0.87) | $0.59 | ($4.08) | - |
| EPS - Diluted | $0.01 | - | $2.04 | $0.17 | $0.38 | - | ($0.87) | $0.58 | ($4.08) | - |
Balance Sheet
| Line item | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 | Q1 '20 | Q4 '19 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $92.08M | $60.13M | $51.76M | $24.23M | $52.43M | $100.39M | $56.44M | $60.27M | $83.03M | $2.49M |
| Accounts Receivable | $58.01M | $62.73M | $63.96M | $53.14M | $44.96M | $25.98M | $36.95M | $36.34M | $80.93M | $97.60M |
| Inventory | - | - | - | - | - | - | $21.42M | $22.09M | $32.35M | $36.41M |
| Accounts Payable | $25.38M | $25.32M | $21.19M | $18.98M | $18.40M | $19.74M | $34.70M | $35.49M | $62.93M | $46.48M |
| Current Assets | $191.18M | $195.90M | $229.29M | $108.90M | $121.91M | $154.25M | $138.00M | $141.87M | $217.28M | $161.74M |
| Total Assets | $595.16M | $598.54M | $631.44M | $523.75M | $539.90M | $578.98M | $1.30B | $1.38B | $1.47B | $1.63B |
| Current Liabilities | $77.26M | $87.42M | $92.83M | $85.47M | $89.13M | $81.83M | $133.19M | $147.57M | $176.03M | $146.36M |
| Long-term Debt | $379.96M | $380.50M | $381.05M | $381.60M | $397.75M | $459.25M | $974.76M | $1.00B | $1.09B | $1.05B |
| Total Liabilities | - | - | - | - | - | - | - | - | - | - |
| Stockholders' Equity | $127.95M | $118.91M | $140.67M | $34.79M | $26.25M | $3.66M | $2.24M | $37.72M | $7.62M | $226.91M |
| Retained Earnings | ($358.59M) | ($359.17M) | ($333.82M) | ($436.59M) | ($444.95M) | ($464.08M) | ($449.26M) | ($406.84M) | ($435.37M) | ($237.28M) |
Cash Flow
| Line item | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 | Q1 '20 | Q4 '19 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $37.02M | - | - | - | $22.62M | - | - | - | $47.02M | - |
| Investing Cash Flow | ($4.11M) | - | - | - | ($3.19M) | - | - | - | ($4.88M) | - |
| Financing Cash Flow | ($966.0K) | - | - | - | ($67.38M) | - | - | - | $38.40M | - |
| CapEx | $2.71M | - | - | - | $1.56M | - | - | - | $4.88M | - |
| Free Cash Flow | $34.30M | - | - | - | $21.06M | - | - | - | $42.15M | - |
Ratios
| Metric | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 | Q1 '20 | Q4 '19 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 38.5% | - | 41.0% | 42.8% | 47.0% | - | 51.8% | 55.0% | 41.0% | - |
| Operating margin | 25.4% | - | 29.3% | 31.4% | 34.4% | - | -7.8% | 21.3% | -56.7% | - |
| EBITDA margin | 27.9% | - | 31.4% | 33.6% | 36.9% | - | -2.5% | 26.2% | -52.4% | - |
| Net margin | 0.5% | - | 81.4% | 7.0% | 17.7% | - | -16.6% | 10.9% | -58.7% | - |
| Free cash flow margin | 26.9% | - | - | - | 19.5% | - | - | - | 12.5% | - |
| FCF / Net income | 59.04 | - | - | - | 1.10 | - | - | - | -0.21 | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | 8.4% | - | 8.4% | 8.0% | 9.0% | - | 10.5% | 8.9% | 8.3% | - |
| Effective tax rate | 93.3% | - | 8.0% | 2.2% | 28.5% | - | - | 17.6% | - | - |
| Return on assets | 0.1% | - | 16.3% | 1.6% | 3.5% | - | -3.3% | 2.1% | -13.5% | - |
| Return on equity | 0.5% | - | 73.1% | 24.0% | 72.9% | - | -1892.8% | 75.6% | -2598.5% | - |
| Return on invested capital | 3.2% | - | 6.5% | 8.8% | 6.3% | - | -1.6% | 4.4% | -13.8% | - |
| Liquidity | ||||||||||
| Current ratio | 2.47 | 2.24 | 2.47 | 1.27 | 1.37 | 1.88 | 1.04 | 0.96 | 1.23 | 1.11 |
| Quick ratio | 2.47 | 2.24 | 2.47 | 1.27 | 1.37 | 1.88 | 0.88 | 0.81 | 1.05 | 0.86 |
| Cash ratio | 1.19 | 0.69 | 0.56 | 0.28 | 0.59 | 1.23 | 0.42 | 0.41 | 0.47 | 0.02 |
| Leverage | ||||||||||
| Debt / Equity | 2.97 | 3.20 | 2.71 | 10.97 | 15.15 | 125.62 | 434.97 | 26.58 | 142.65 | 4.62 |
| Debt / Assets | 0.64 | 0.64 | 0.60 | 0.73 | 0.74 | 0.79 | 0.75 | 0.73 | 0.74 | 0.64 |
| Debt / EBITDA | 10.67 | - | 9.60 | 9.45 | 9.98 | - | - | 14.58 | - | - |
| Interest coverage | 4.6x | - | 5.0x | 4.0x | 3.5x | - | -1.0x | 2.6x | -8.8x | - |
| Equity multiplier | 4.65 | 5.03 | 4.49 | 15.06 | 20.56 | 158.37 | 578.66 | 36.62 | 192.59 | 7.17 |
| Liabilities / Assets | - | - | - | - | - | - | - | - | - | - |
| Efficiency | ||||||||||
| Asset turnover | 0.21 | - | 0.20 | 0.23 | 0.20 | - | 0.20 | 0.19 | 0.23 | - |
| Inventory turnover | - | - | - | - | - | - | 5.73 | 5.35 | 6.16 | - |
| Days sales outstanding | 166d | - | 185d | 162d | 152d | - | 53d | 51d | 87d | - |
| Days inventory outstanding | - | - | - | - | - | - | 64d | 68d | 59d | - |
| Days payable outstanding | 118d | - | 104d | 101d | 117d | - | 103d | 110d | 115d | - |
| Cash conversion cycle | - | - | - | - | - | - | 13d | 9d | 31d | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 18.0% | - | -50.5% | -54.3% | -68.0% | - | -16.1% | -22.9% | 57.7% | - |
| Revenue CAGR (3y) | -15.9% | - | -2.8% | - | -10.3% | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | -3.4% | - | -60.8% | -64.4% | -63.3% | - | 5.5% | -38.8% | 87.8% | - |
| Operating income growth (YoY) | -12.9% | - | - | -32.6% | - | - | - | 11.9% | - | - |
| Net income growth (YoY) | -97.0% | - | - | -70.7% | - | - | - | 57.2% | - | - |
| EPS growth (YoY) | -97.4% | - | - | -70.7% | - | - | - | 56.8% | - | - |
| EPS CAGR (3y) | -53.6% | - | 51.2% | -32.0% | -8.1% | - | - | 21.9% | - | - |
| EPS CAGR (5y) | -51.7% | - | - | - | - | - | - | 125.3% | - | - |
| FCF growth (YoY) | 62.9% | - | - | - | -50.0% | - | - | - | 3132.2% | - |
| FCF CAGR (5y) | 80.5% | - | - | - | 86.0% | - | - | - | - | - |
| Book value growth (YoY) | 387.3% | 3152.4% | 6177.1% | -7.8% | 244.4% | -98.4% | -99.6% | -92.9% | -98.5% | -38.5% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2021-12-31.
Product / service
$481.25M totalSilver Sneakers$362.77M · 75.4%
Prime Fitness$94.25M · 19.6%
Whole Health Living$23.78M · 4.9%
Product And Service Other$454.0K · 0.1%
Peer comparison
Same SIC group: Services-Misc Health & Allied Services, NEC
Comparing TIVITY HEALTH against the 5 most active filers in the same SIC group.